艾迪注射液与肝动脉栓塞化疗联合治疗原发性肝癌的系统评价

Meta-analysis on Aidi Injection Combined with Transcatheter Arterial Chemoembolization in Treatment of Primary Liver Cancer

目的:系统评价艾迪注射液与肝动脉栓塞化疗(transcatherter arterial chemoembolization,TACE)联合治疗原发性肝癌的疗效与安全性。方法:计算机检索维普资讯中文科技期刊数据库、中国期刊全文数据库、万方数据库、Pub Med、Embase、Cochrane等,搜集艾迪注射液与TACE联合治疗原发性肝癌的随机对照研究,检索时间从建库至2016年7月。由2位研究者独立筛选文献、提取资料、评价文献质量。采用Cochrane系统评价方法,采用Rev Man 5.0软件对所提取的数据进行文献荟萃(Meta)分析。结果:共纳入的19个研究、1 351例研究对象。Meta分析结果显示,与对照组(单纯TACE)比较,观察组方案(艾迪注射液联合TACE)可明显提高近期有效率、改善生活质量及临床症状、提高1年及2年生存率,差异均有统计学意义(P<0.05)。在减轻TACE所致不良反应方面,艾迪注射液与TACE联合治疗能显著减轻TACE治疗后骨髓抑制及肝损害,与对照组比较,差异有统计学意义(P<0.05);而对发热、胃肠道反应的缓解效果不明显。结论:与单纯TACE比较,艾迪注射液与TACE联合治疗原发性肝癌,可在一定程度上提高TACE治疗效果,提高患者的生活质量,并可在一定程度上缓解TACE所致不良反应。

OBJECTIVE： To systematically review the efficacy and safety of Aidi injection combined with transcatheter arterial chemoembo Iization（ TACE） in treatment of primary liver cancer. METHODS： VIP data base,CNKI,Wanfang data base,Pub Med,Embase and Cochrane were retrieved by computers to collect the RCT s of Aidi injection combined with TACE in treatment of primary liver cancer till Jul. 2016. After two reviewers separately screened literature according to the inclusion and exclusion criteria,extracted data and assessed the quality of the included studies,data were analyzed with Rev Man 5. 3 software by Cochrane. RESULTS： Totally 19 RCTs were included with 1 351 patients involved. According to Meta-analysis,compared with control group（ TACE monotherepy）,the total effective rate,living quality,clinical manifestation,one-year and two-years living rate were superior in the observation group（ Aidi injection combined with TACE）,the difference was statistically significant（ P〈0. 05）. As for the adverse drug reactions induced by TACE,Aidi injection combined with TACE can significantly reduce the myelosuppression and the liver injure after treatment; compared with the control group,the difference was statistically significant（ P〈0. 05）. However,the relief effects were not obvious in pyrexia and alimentary tract. CONCLUSIONS： Compared with TACE monotherapy,Aidi injection combined with TACE in treatment of primary liver cancer can improve the treatment effects to some extent,improve patients＇ life quality and relieve the adverse reactions induced by TACE.